Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...

ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsAlbert Bourla - Chairman of the Board ...

Regencell Bioscience ( RGC 0.65%), a China-based drugmaker, has been on fire over the past 12 months, with its share price ...

Beam also unveiled a new platform-based approach to phenylketonuria treatments and a $500 million senior secured credit facility.

The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities, ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity ...

CHONGQING, CHINA - JANUARY 29: In this photo illustration, a smartphone displays the logo of Pfizer Inc. (NYSE: PFE), an American multinational pharmaceutical company engaged in the development, ...